In case you missed it: Nov. 29 to Dec. 3

Article

Wondering what you missed this week?

This week's top stories included:

Vitamin D and green tea extract for treatment of uterine fibroids

Vitamin D and green tea extract resulted in a significant reduction in the mean size of uterine fibroids among women of later reproductive age, according to a recent study.

Read now

Exploring the connection between endometriosis and the gut microbiome

Although bacteria are altered in endometriosis, there is no definitive consensus on specific microbiota compositions linked to the disease, according to a review in Human Reproduction Update.

Read now

FDA investigating impact of Omicron on available mitigation strategies

The US Food and Drug Administration (FDA) is currently investigating whether the new COVID-19 variant will evade current mitigation strategies and diagnostic tools.

Read now

FDA grants olaparib priority review in BRCA-mutated HER2-negative high-risk early breast cancer

Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

Read more

Midlife vision impairment and depressive symptoms

Midlife women with early-stage vision impairment are significantly more likely to develop depressive symptoms, according to a study in the journal Menopause, which used data from the Michigan site of the Study of Women’s Health Across the Nation (SWAN).

Read more

Recent Videos
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Lauren Streicher, MD
© 2024 MJH Life Sciences

All rights reserved.